Death: Diamond Shruumz microdosing candies under FDA investigation

The microdosing candy Diamond Shruumz is currently under investigation by the FDA after new reports emerged of a connection to a death that was “possibly” linked to the controversial candy.

The Associated Press reports that the candy has now been officially recalled because it contains muscimol, a poison found in some mushrooms. There is speculation that the ingredient may be linked to the death and the 27 reported hospitalizations.

Severe symptoms reported by those affected included seizures, anxiety, irregular heart rhythms and loss of consciousness. According to FDA officials, the most recent illness was reported on Monday, July 1.

In addition, at least 48 people in 24 states reported becoming ill after eating Diamond Shruumz branded chocolate bars, wafers and candies.

Last month, Diamond Shruumz denied allegations that its controversial candy was dangerous, claiming it was a “safe and enjoyable experience” and free of psychoactive drugs.

“There is no psilocybin, death cap mushrooms or other prescription drugs included, ensuring a safe and enjoyable experience. Rest assured, not only are our treats free of psychedelic substances, but our carefully crafted ingredients still provide an experience,” a statement on the company’s website reads.

At the same time, however, six people were hospitalized for an alleged overdose of the product. The FDA then issued a public warning about the candy.

“The FDA is working to determine the cause of these illnesses and is considering appropriate next steps. More information will be provided as it becomes available,” the statement in the alert said.

The microdosing market has grown significantly in recent years as companies try to get drugs like MDMA approved for medical use. Business Insider calls 2020 the “psychedelic renaissance” due to the surge in interest in psychedelics. According to Pitchbook data, investments in psychedelic startups totaled $163.6 million in the first three quarters of this year.

Microdosing is the regular intake of tiny doses of a drug – typically a psychedelic – without experiencing any effects.

Some people believe that microdosing can improve mental health and creativity. This practice has gained popularity in Silicon Valley, where a number of CEOs have incorporated microdosing into their regular morning routine.